Pipeline

Progress of Programs

Stage
Sep 30, 2020
Dec 31, 2020
Total Number of Ongoing Programs
117 120
Target Validation-to-Hit Stage
40 39
Hit-to-Lead Stage
54 58
Lead-to-GLP-Tox Stage
13 13
GLP-Tox-to-IND Stage
8 8
Phase 1 Clinical Study
2 2
Phase 2 Clinical Study
0 0
Phase 3 Clinical Study
0 0

(注)上記のプログラム数は、PDPSの非独占的技術ライセンス先でのプログラムを含んでおりません。
N.B. The figures in the above table DO NOT include programs in the PDPS Technology Transfer segment.